GlassScriptPhysician profile
Ernest Doyle Graves
NPI 1578547188
$1,451.71
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $379 · 2021: $457 · 2022: $421.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $224.60 | 2021-2022 | |
| Baxter Healthcare | $145.19 | 2020-2022 | |
| Trevena, INC. | $140.13 | 2021 | |
| Vioptix INC | $112.92 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.80 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.57 | 2020-2022 | |
| Tela Bio, INC. | $72.99 | 2019-2022 | |
| Davol INC. | $50.33 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $44.38 | 2021 | |
| Ethicon US, LLC | $41.63 | 2019-2021 | |
| Integra Lifesciences Corporation | $40.30 | 2021-2022 | |
| Zyla Life Sciences, INC. | $39.51 | 2020 | |
| Covidien LP | $38.23 | 2019-2020 | |
| Heron Therapeutics, INC. | $31.94 | 2022 | |
| Medtronic USA, INC. | $29.59 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $29.51 | 2020 | |
| La Jolla Pharmaceutical Company | $23.97 | 2020 | |
| Thd America, INC. | $23.06 | 2020 | |
| Romark Laboratories, Lc | $22.90 | 2019 | |
| Edwards Lifesciences Corporation | $21.52 | 2020 | |
| Shire North American Group INC | $21.26 | 2019 | |
| Medspira, LLC | $19.94 | 2022 | |
| Mallinckrodt Enterprises LLC | $17.19 | 2019 | |
| Baudax Bio INC. | $16.44 | 2020 | |
| Braintree Laboratories, INC. | $13.09 | 2019 | |
| Alfasigma USA, INC. | $11.72 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.